Chronic hepatitis B virus (HBV) infection is a common cause of liver disease globally, with a
disproportionately high burden in South-East Asia. Vaccines and nucleoside or nucleotide …

Infection is a main concern after haemopoietic stem cell transplantation (HSCT) and a major
cause of transplant-related mortality. Some of these infections are preventable by …

During hepatitis B virus (HBV) infection, the presence of HBV-specific antibody producing B
cells and functional HBV-specific T cells (with helper or cytotoxic effects) ultimately …

The liver is an immunologically tolerant organ that is uniquely equipped to limit
hypersensitivity to food-derived antigens and bacterial products through the portal vein and …

Fewer than 1% of chronic hepatitis B virus infections per year are cured with antiviral
treatment. This creates a need for long-term treatment, which poses challenges for patients …

Hepatitus B virus (HBV) reactivation is a well‐described complication in cancer patients who
receive cytotoxic chemotherapy and may result in varying degrees of liver damage. As …

It is estimated conservatively that more than one third of the world's population has been
infected with the hepatitis B virus (HBV) and that there are 350 million people with chronic …

The prevalence of hepatitis B virus (HBV) infection in patients with haematological
malignancies is increased compared with the general population worldwide. HBV …

APPROXIMATELY 10,000 autologous hematopoietic stem cell (HSC) transplants are
performed worldwide each year for malignant diseases. 1 Results of randomized trials in …

While new therapies for chronic hepatitis C virus infection have delivered remarkable cure
rates, curative therapies for chronic hepatitis B virus (HBV) infection remain a distant goal …